Digital therapeutics : strategic, scientific, developmental, and regulatory aspects /

One of the hallmarks of the 21st century medicine is the emergence of digital therapeutics (DTx)--evidence-based, clinically validated digital technologies to prevent, diagnose, treat, and manage various diseases and medical conditions. DTx solutions have been gaining interest from patients, investo...

Full description

Saved in:
Bibliographic Details
Online Access: Full text (MCPHS users only)
Other Authors: Sverdlov, Oleksandr, Dam, Joris van
Format: Electronic eBook
Language:English
Published: Abingdon : CRC Press, 2022
Series:Chapman & Hall/CRC biostatistics series.
Subjects:

MARC

LEADER 00000cam a2200000 a 4500
001 p2979904
005 20240206155114.0
006 m o d
007 cr |n|||||||||
008 220921t20222023enka ob 000 0 eng d
015 |a GBC2G8132  |2 bnb 
016 7 |a 020751912  |2 Uk 
020 |a 9781000799231  |q (electronic bk.) 
020 |a 1000799239  |q (electronic bk.) 
020 |a 9781003017288  |q (electronic bk.) 
020 |a 1003017282  |q (electronic bk.) 
020 |a 9781000799378  |q (electronic bk. : EPUB) 
020 |a 1000799379  |q (electronic bk. : EPUB) 
020 |z 0367861593 
020 |z 9780367861599 
024 7 |a 10.1201/9781003017288  |2 doi 
035 |a (OCoLC)on1345215085 
035 |a (OCoLC)1345215085 
037 |a 9781003017288  |b Taylor & Francis 
040 |a YDX  |b eng  |c YDX  |d TYFRS  |d OCLCF  |d UKMGB  |d UKAHL  |d OCLCQ  |d MPA  |d UtOrBLW 
049 |a MPAA 
050 4 |a R858 
072 7 |a MAT  |x 029000  |2 bisacsh 
072 7 |a PBT  |2 bicssc 
082 0 4 |a 610.285  |2 23/eng/20220930 
245 0 0 |a Digital therapeutics :  |b strategic, scientific, developmental, and regulatory aspects /  |c edited by Oleksandr Sverdlov and Joris van Dam. 
264 1 |a Abingdon :  |b CRC Press,  |c 2022. 
264 4 |c ©2023 
300 |a 1 online resource (429 pages) :  |b illustrations (some color). 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
490 1 |a Chapman & Hall/CRC biostatistics series 
504 |a Includes bibliographical references. 
520 |a One of the hallmarks of the 21st century medicine is the emergence of digital therapeutics (DTx)--evidence-based, clinically validated digital technologies to prevent, diagnose, treat, and manage various diseases and medical conditions. DTx solutions have been gaining interest from patients, investors, healthcare providers, health authorities, and other stakeholders because of the potential of DTx to deliver equitable, massively scalable, personalized and transformative treatments for different unmet medical needs. Digital Therapeutics: Scientific, Statistical, Clinical, and Regulatory Aspects is an unparalleled summary of the current scientific, statistical, developmental, and regulatory aspects of DTx which is poised to become the fastest growing area of the biopharmaceutical and digital medicine product development. This edited volume intends to provide a systematic exposition to digital therapeutics through 19 peer-reviewed chapters written by subject matter experts in this emerging field. This edited volume is an invaluable resource for business leaders and researchers working in public health, healthcare, digital health, information technology, and biopharmaceutical industries. It will be also useful for regulatory scientists involved in the review of DTx products, and for faculty and students involved in an interdisciplinary research on digital health and digital medicine. 
545 0 |a Dr. Oleksandr Sverdlov is Neuroscience Disease Area Lead Statistician in early clinical development at Novartis. He received B.Sc. in Applied Mathematics from V.N. Karazin Kharkiv National University, Ukraine, M.Sc. in Statistics from University of Maryland, Baltimore County (UMBC), and Ph.D. in Information Technology with Concentration in Statistical Science from George Mason University. He has been actively involved in methodological research and applications of innovative statistical approaches in drug development. He is the editor of a monograph "Modern Adaptive Randomized Clinical Trials: Statistical and Practical Aspects" (CRC Press/Chapman & Hall, 2015) and a co-author of a book "Mathematical and Statistical Skills in the Biopharmaceutical Industry: A Pragmatic Approach" (CRC Press/Chapman & Hall, 2019). His most recent work involves design and analysis of proof-of-endpoint clinical studies evaluating novel digital technologies. Joris van Dam is a Digital Health Intrapreneur, helping organizations deliver upon the promise of digital health technologies to transform the experience and treatment outcomes of the patients we collectively serve. For the past several years, Joris has led the Digital Therapeutics research program at the Novartis Institutes of Biomedical Research in Cambridge, MA. In the 10+ years before that, Joris worked on a wide variety of Digital Health solutions improving the clinical treatment and the clinical research experience of patients and providers in the U.S., Europe, India, and Africa. Joris received a Ph.D. in Computer Science / Artificial Intelligence from the University of Amsterdam in 1998, after which he spent several years in consulting and program management before recognizing the promise and the urgency of digital health solutions to improve the health of our nations. 
650 0 |a Medical informatics.  |0 sh 89005069  
650 0 |a Telecommunication in medicine.  |0 sh 93009003  
700 1 |a Sverdlov, Oleksandr.  |0 n 2015186228 
700 1 |a Dam, Joris van.  |0 n 2022182811 
776 0 8 |i Print version:  |z 0367861593  |z 9780367861599  |w (OCoLC)1330197840 
830 0 |a Chapman & Hall/CRC biostatistics series.  |0 no2006134495 
951 |a 2979904 
994 |a C0  |b MPA 
999 f f |i 931bb63c-142c-5195-a155-701f16d3d58f  |s 05f8e7f8-ba1c-5b3c-b5f9-b18ea68945ca  |t 0 
952 f f |a Massachusetts College of Pharmacy and Health Sciences  |b Online  |c Online  |d E-Collections  |t 0  |e Taylor & Francis  |h Other scheme 
856 4 0 |t 0  |u https://ezproxymcp.flo.org/login?url=https://www.taylorfrancis.com/books/9781003017288  |y Full text (MCPHS users only)